Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
Dimple Butani,1 Nidhi Gupta,2 Gaurav Jyani,1 Pankaj Bahuguna,1 Rakesh Kapoor,3 Shankar Prinja1 1Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Department of Radiation Oncology, Government Medical College and...
Enregistré dans:
Auteurs principaux: | Butani D, Gupta N, Jyani G, Bahuguna P, Kapoor R, Prinja S |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9477f24e1a394e24902920eacd82c44f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
par: Maura Harrigan, et autres
Publié: (2021) -
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
par: Naiba Nabieva, et autres
Publié: (2021) -
Association of Endocrine Therapy and Dementia in Women with Breast Cancer
par: Thompson MR, et autres
Publié: (2021) -
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
par: Mo QG, et autres
Publié: (2016) -
Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
par: Stefano Gonnelli, et autres
Publié: (2008)